Predictor of response to immunotherapy in Triple Negative Breast Cancer: Study of innate and adaptive immunity.

Background Triple Negative Breast Cancer (TNBC) accounts for 10-20% of all breast tumors and is associated with a poor prognosis, with a median survival in the range of 3 years. Recently, a significant improvement in overall survival was reported with the combination of immune checkpoint inhibitors (ICI) and CT, but the transformative effect observed in other types of advanced tumours, was not detected. Hypothesis Our research hypothesis is that it is possible to identify, through the discovery of suitable biomarkers, among TN MBC PD-L1 positive patients, who currently show an overall response rate to the combination of ICI + CT in the range of 50 to 60%, a subgroup of women characterized by a higher probability of response.